Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Common Equity (2023 - 2026)

ArriVent BioPharma has reported Common Equity over the past 4 years, most recently at $324.0 million for Q1 2026.

  • Quarterly results put Common Equity at $324.0 million for Q1 2026, up 59.96% from a year ago — trailing twelve months through Mar 2026 was $324.0 million (up 59.96% YoY), and the annual figure for FY2025 was $307.2 million, up 19.24%.
  • Common Equity reached $324.0 million in Q1 2026 per AVBP's latest filing, up from $307.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $324.0 million in Q1 2026 and bottomed at -$153.2 million in Q4 2023.
  • Median Common Equity over the past 4 years was $257.7 million (2024), compared with a mean of $156.7 million.
  • The largest annual shift saw Common Equity soared 427.25% in 2024 before it tumbled 36.25% in 2025.
  • Over 4 years, Common Equity stood at -$153.2 million in 2023, then skyrocketed by 268.19% to $257.7 million in 2024, then grew by 19.24% to $307.2 million in 2025, then grew by 5.45% to $324.0 million in 2026.
  • Business Quant data shows Common Equity for AVBP at $324.0 million in Q1 2026, $307.2 million in Q4 2025, and $305.0 million in Q3 2025.